vs
Side-by-side financial comparison of Entrada Therapeutics, Inc. (TRDA) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $20.6M, roughly 1.3× Entrada Therapeutics, Inc.). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -84.4%, a 123.6% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs -65.2%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-39.7M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs 6.4%).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
TRDA vs WTBA — Head-to-Head
Income Statement — Q1 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.6M | $26.9M |
| Net Profit | $-17.3M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | -106.0% | 50.0% |
| Net Margin | -84.4% | 39.2% |
| Revenue YoY | -65.2% | 16.6% |
| Net Profit YoY | -173.8% | 34.8% |
| EPS (diluted) | $-0.42 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | — | $24.2M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | — | $23.8M | ||
| Q1 25 | $20.6M | $23.1M | ||
| Q4 24 | $37.4M | $20.9M | ||
| Q3 24 | $19.6M | $20.3M | ||
| Q2 24 | $94.7M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | — | $7.4M | ||
| Q3 25 | — | $9.3M | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | $-17.3M | $7.8M | ||
| Q4 24 | $1.1M | $7.1M | ||
| Q3 24 | $-14.0M | $6.0M | ||
| Q2 24 | $55.0M | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | — | 39.6% | ||
| Q3 25 | — | 45.8% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | -106.0% | 43.4% | ||
| Q4 24 | -15.7% | 30.9% | ||
| Q3 24 | -110.7% | 36.6% | ||
| Q2 24 | 56.4% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 37.3% | ||
| Q2 25 | — | 33.5% | ||
| Q1 25 | -84.4% | 34.0% | ||
| Q4 24 | 3.0% | 34.0% | ||
| Q3 24 | -71.7% | 29.3% | ||
| Q2 24 | 58.1% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | — | $0.44 | ||
| Q3 25 | — | $0.55 | ||
| Q2 25 | — | $0.47 | ||
| Q1 25 | $-0.42 | $0.46 | ||
| Q4 24 | $-0.20 | $0.41 | ||
| Q3 24 | $-0.35 | $0.35 | ||
| Q2 24 | $1.55 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $67.8M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $417.3M | $270.7M |
| Total Assets | $486.5M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | — | $471.1M | ||
| Q3 25 | — | $232.9M | ||
| Q2 25 | — | $345.2M | ||
| Q1 25 | $67.8M | — | ||
| Q4 24 | $101.2M | $243.5M | ||
| Q3 24 | $78.0M | — | ||
| Q2 24 | $185.3M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | — | $266.0M | ||
| Q3 25 | — | $255.1M | ||
| Q2 25 | — | $240.9M | ||
| Q1 25 | $417.3M | $237.9M | ||
| Q4 24 | $428.7M | $227.9M | ||
| Q3 24 | $422.4M | $235.4M | ||
| Q2 24 | $429.9M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | — | $4.1B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | $486.5M | $4.0B | ||
| Q4 24 | $526.3M | $4.0B | ||
| Q3 24 | $554.6M | $4.0B | ||
| Q2 24 | $582.0M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.5M | $12.9M |
| Free Cash FlowOCF − Capex | $-39.7M | $12.4M |
| FCF MarginFCF / Revenue | -192.9% | 46.0% |
| Capex IntensityCapex / Revenue | 5.6% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-58.0M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | — | $46.5M | ||
| Q3 25 | — | $11.4M | ||
| Q2 25 | — | $13.5M | ||
| Q1 25 | $-38.5M | $9.7M | ||
| Q4 24 | $-31.6M | $39.8M | ||
| Q3 24 | $-24.3M | $12.9M | ||
| Q2 24 | $39.8M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | — | $43.2M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | — | $12.8M | ||
| Q1 25 | $-39.7M | $8.3M | ||
| Q4 24 | $-32.2M | $13.7M | ||
| Q3 24 | $-24.9M | $7.0M | ||
| Q2 24 | $38.8M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | — | 178.3% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 53.6% | ||
| Q1 25 | -192.9% | 35.7% | ||
| Q4 24 | -86.2% | 65.6% | ||
| Q3 24 | -127.3% | 34.2% | ||
| Q2 24 | 41.0% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | 5.6% | 6.5% | ||
| Q4 24 | 1.7% | 125.3% | ||
| Q3 24 | 3.3% | 29.4% | ||
| Q2 24 | 1.1% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | -27.94× | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | 0.72× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
